Adults with obesity and type 2 diabetes saw big gains in glycemic control and body weight on the experimental triple agonist, researchers reported.
Recap by typeshit. Post by Facebook on Facebook.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
13:00
A short video on what else people may be losing besides fat while on tirzepatide, a point raised often around muscle loss on GLP-1 drugs.
In 2,749 adults with type 2 diabetes and high heart risk, Lilly's pill had fewer heart events and less low blood sugar, but GI side effects hit 62% of users.
Loading…